




pR3GHP-NlucP
3657 bp




pNL1.2-R3G[NlucP]
3582 bp








p3GHP-Luc
6766 bp




pNL1.2[NlucP]
3233 bp




pIDT-SMART-3xGIRE
3006 bp








pR3GrLPK-NlucP
3477 bp




pNL1.2-R3G[NlucP]
3582 bp





p3GrLPK-Luc
6609 bp






pNL1.2[NlucP]
3233 bp




pIDT-SMART-3xGIRE
3006 bp













pAAV8-R3GHLP-hINSco
5605 bp




pAAV8-HLP-hINSco
5410 bp




pAAV8-R3GHLP-Luc
6957 bp






pR3GHLP-NlucP-e (+)
4509 bp

INSERT FRAGMENT
Insert at FseI (1191), overhangs removed




pR3GHLP-NlucP
3657 bp


Insert EcoRI (961), filled-in – XbaI (1813), filled-in




3'iALB Shutter vector
4298 bp




pR3GHLP-NlucP-e (-)
4509 bp







pAAV8-R3GHLP-Luc
6957 bp




pAAV8-HLP-Luc
6762 bp




pR3GHLP-NlucP
3657 bp




pAAV8-R3GHLP-Luc-e(+)
7817 bp






Supplementary Figure S1. Schematic diagram of cloning for plasmids used in this study. (A) pIDT-SMART-3xGIRE; (B) pR3GHLP-NlucP; (C) pR3GhLPK-NlucP; (D) pR3GrLPK-NlucP; (E) pSV40-NlucP; (F) pSV40-Luc2; (G) pHLP-NlucP; (H) pAAV8-R3GHLP-hINSco; (I) 3'iALB shutter vector; (J) pR3GHLP-NlucP-e(+); (K) pR3GHLP-NlucP-e(-); (L) pAAV8-R3GHLP-Luc; (M) pAAV8-R3GHLP-Luc-e(+); (N) pAAV8-R3GHLP-hINSco-e(+).



Supplementary Figure S2. Detail body weight and blood glucose profiles of mouse 3 in AAV8-HLP-hINSco (7.5×10^9) injected group compared to mouse 1 and 2 in the same group. **(A)** Body weight for individual mouse. **(B)** Blood glucose for individual mouse. Mouse 1 was euthanized before endpoint at 140 days post adeno-associated virus serotype 8 (AAV8) injection as it showed dehydration and more than 20% weight loss according to NUS Institutional Animal Care and Use Committee (IACUC) guidelines.



Supplementary Figure S3. Functionality assessment of 3' albumin enhancer (3'iALB) in AAV plasmid vector with R3GHLP glucose responsive promoter and firefly luciferase as reporter gene for its enhanced gene expression and glucose responsiveness. **(A)** Glucose responsive gene expression level of pAAV-R3GHLP-Luc-e(+)(forward direction only) containing 3'iALB at 5.5 versus 25 mM glucose. The expression was compared to pAAV-R3GHLP-Luc without 3'iALB. $n = 3$. **(B)** Glucose induction and withdrawal effect in pAAV-R3GHLP-Luc-e(+). After overnight transfection, glucose was increase from 5.5 mM to 25 mM in induction group (add glucose) whereas glucose was reduced from 25 mM to 5.5 mM in withdrawal group (withdraw glucose). Luciferase activities were measured at 0, 3, 6, 12, 24, 36, and 48 h, $n = 6$. All experiments were performed in vitro with freshly isolated primary rat hepatocytes culture where plasmids were transfected using lipofectamin 3000. Firefly luciferase (Fluc) was used as reporter gene and the expression levels were normalized to PEST-destabilized nanoLuc luciferase (NlucP) activities from co-transfected pSV40-NlucP constitutively expressed control reporter plasmid. All data were presented as mean \pm s.e.m. Statistical significances were determined by Student's unpaired *t*-test where ** indicates $p < 0.01$ and considered very significant and *** indicates $p < 0.001$ and considered extremely significant.